RSK1 and RSK2 are associated with cell growth, survival, and proliferation [12,37], whereas RSK4 expression is reduced in ovarian cancer, colorectal cancer, acute myeloid leukemia, and breast cancer [18,37]. Here, RPS6KA6 is linked to breast carcinoma.